Clinical trials: Lung Metastasis
Non-Small Cell Lung Cancer, Brain Metastases
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
This is a non-randomized open-label uncontrolled phase II trial evaluating efficacy and toxicity of erlotinib in patients with asymptomatic brain metastasis advanced NSCLC who was benefitted by first line chemotherapy.
- Trial name
- NCT00663689
- Testing
- erlotinib
- Volunteers
- 45 people
- Sponsor
- Guangdong Provincial People's Hospital
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Lung Adenocarcinomas
Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas
Lung cancer is the leading cause of cancer mortality in France and worldwide. 60% of patients present themselves with a disease diagnosis immediately metastatic non curable. Adenocarcinomas account for 50% of incident tumors.
- Trial name
- NTS (NCT02891733)
- Sponsor
- Fondation Hôpital Saint-Joseph
Nonsmall Cell Lung Cancer
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following…
- Trial name
- NCT02981108
- Testing
- HS-10296
- Where
- 10 sites in United States
- Volunteers
- 364 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Lung Cancer
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
- Trial name
- NCT06644768
- Testing
- valemetostat tosylate, pembrolizumab
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 137 people
- Sponsor
- Daiichi Sankyo
Non-squamous Cell Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic…
- Trial name
- NCT03792074
- Testing
- SCT510, Bevacizumab, Paclitaxel
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
Non-Small Cell Lung Cancer Metastatic
Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
This is a study of repeated IT administrations of BO-112 in combination with ablative radiotherapy (SABR) and concurrent nivolumab in patients with metastatic PD-1/PD-L1-refractory NSCLC.
- Trial name
- Noelia (NCT05265650)
- Testing
- BO-112 in combination with ablative radiotherapy (SABR) and nivolumab, Tissue Biopsies
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Overal Survival, Non-small Cell Lung Cancer
Bone Metastasis on the Survival of Gefitinib Effective Patients
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective…
- Trial name
- NCT03157310
- Testing
- Gefitinib
- Volunteers
- 265 people
- Sponsor
- Qilu Hospital of Shandong University
Metastatic Pulmonary Nodules
Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules
The purpose of this study is to apply the techniques of dynamic MRI imaging enhancement to research participants with one or more pulmonary nodule to determine if meaningful information about the nature of the nodule can be…
- Trial name
- NCT00751920
- Testing
- Enhanced MRI Scan
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Metastatic Non Small Cell Lung Cancer
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
This clinical trial is comparing morning infusions of the study drug (pembrolizumab) to random infusion scheduling for patients with non-small cell lung cancer.
- Trial name
- TIME-NSCLC (NCT06882174)
- Testing
- Scheduling of the time of pembrolizumab infusions
- Volunteers
- 58 people
- Sponsor
- AHS Cancer Control Alberta
Whole-Brain Radiotherapy
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
This study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone in small cell lung cancer (SCLC) patients with…
- Trial name
- NCT07443397
- Testing
- Anlotinib, Whole-brain Radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada.
- Trial name
- PANORAMA (NCT03053297)
- Testing
- Patient Reported Outcomes
- Where
- 110 sites in Canada, China and 4 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
This is a Phase 2, open-label study to evaluate the efficacy and the safety/tolerability of pyrotinib in previously treated NSCLC patients with EGFR exon 20 insertion mutations or HER2 exon 20 insertion mutations.
- Trial name
- NCT04063462
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System
Stereotactic Body Radiotherapy (SBRT) delivers an ablative dose of radiation to tumours, with high precision. This technique offers an alternative to surgery for lung lesions.
- Conditions
- Lung Cancer, Stereotactic Body Radiotherapy, Lung Diseases, Lung Cancer Metastatic
- Trial name
- SBRT_LOV (NCT06722885)
- Testing
- Standard radiotherapy treatment
- Where
- Belgium
- Sponsor
- Universitair Ziekenhuis Brussel
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group
NSCLC
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that achieve stable disease after 8 weeks…
- Trial name
- NCT01690390
- Testing
- Icotinib of routine dose, Icotinib of high dose
- Where
- 17 sites in China
- Volunteers
- 180 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.